9.34%
41.63%
-32.93%
-57.71%
-82.60%
-98.92%
-98.48%
AI Spotlight on MYNZ
Company Description
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics.It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests.The company was founded in 2008 and is based in Mainz, Germany.
Market Data
| Last Price | 6.09 |
| Change Percentage | 9.34% |
| Open | 5.75 |
| Previous Close | 5.57 |
| Market Cap ( Millions) | 14 |
| Volume | 358813 |
| Year High | 7.95 |
| Year Low | 0.18 |
| M A 50 | 4.14 |
| M A 200 | 1.37 |
Financial Ratios
| FCF Yield | -176.19% |
| Dividend Yield | 0.00% |
| ROE | -303.20% |
| Debt / Equity | 228.39% |
| Net Debt / EBIDTA | -1.40% |
| Price To Book | 30.44 |
| Price Earnings Ratio | -3.76 |
| Price To FCF | -0.57 |
| Price To sales | 15.11 |
| EV / EBITDA | -0.55 |
News
- Jan -27 - Mainz Biomed N.V. Regains Compliance with Nasdaq Capital Market Listing Requirements
- Jan -21 - Mainz Biomed Initiates U.S. Clinical Study to Evaluate Performance of Next Generation Test on Advanced Adenomas over Large Patient Population
- Dec -19 - Mainz Biomed Forms Agreement with Quest Diagnostics to Provide Clinical Trials Laboratory Services for Colorectal Cancer Screening Test
- Dec -16 - Mainz Biomed Announces Closing of $8.0 Million Follow-On Offering
- Dec -13 - Mainz Biomed Announces Pricing of $8.0 Million Follow-On Offering Priced at-the-Market Under Nasdaq Rules
- Dec -03 - Mainz Biomed Announces Reverse Stock Split Soon After Collaborating With MedTech Giant Thermo Fisher Scientific
- Nov -29 - Mainz Biomed Announces Stock Split
- Oct -21 - Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
- Oct -08 - Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
- Oct -01 - Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
- Sep -04 - Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
- Jul -25 - Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
- Jul -09 - Mainz Biomed Announces Submission for FDA Breakthrough Device Designation for its Next Generation CRC Screening Test
- Jul -02 - Mainz Biomed Provides Half Year 2024 Corporate Update
- Jun -03 - Mainz Biomed Presented Industry Leading Results of its Pooled Study at ASCO 2024
- May -31 - Mainz Biomed Reports Results of 2024 Annual General Meeting
- May -28 - Mainz Biomed to Present New Pooled Colorectal Cancer Screening Data, its Largest Study to Date, at ASCO 2024 Annual Meeting
- May -20 - Mainz Biomed Awarded Poster of Distinction at Digestive Disease Week, Positioning the Company for its Planned FDA Trial
- May -07 - Mainz Biomed to Present Results of Colorectal Cancer Screening Study eAArly DETECT at Digestive Disease Week 2024 in Washington, D.C.
- Apr -25 - Mainz Biomed Reports Positive Topline Results from Pooled Study Evaluating Novel mRNA Biomarkers and Proprietary AI Algorithm for Integration into Pivotal FDA PMA Clinical Trial for Next Generation Colorectal Cancer Diagnostic
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Genetic Diagnostic Testing
Expected Growth : 10.27 %
What the company do ?
Genetic Diagnostic Testing from Mainz Biomed B.V. detects cancer-related genetic mutations in blood or tissue samples, enabling early cancer detection and personalized treatment.
Why we expect these perspectives ?
Mainz Biomed B.V.'s 10.27% growth in Genetic Diagnostic Testing is driven by increasing demand for non-invasive cancer diagnostics, advancements in genetic sequencing technologies, and growing adoption in emerging markets. Additionally, rising incidence of cancer and genetic disorders, coupled with government initiatives to promote early disease detection, are fueling growth in this segment.
Mainz Biomed B.V. Products
| Product Range | What is it ? |
|---|---|
| Colorectal Cancer Screening Test | A non-invasive, stool-based DNA test for the early detection of colorectal cancer |
| Colorectal Cancer Recurrence Test | A blood-based test for the detection of circulating tumor DNA in patients with a history of colorectal cancer |
| CRC-Protect | A blood-based test for the detection of methylated Septin 9, a biomarker for colorectal cancer |
Mainz Biomed B.V.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Mainz Biomed B.V. is medium due to the availability of alternative diagnostic tests and treatments for cancer.
Bargaining Power Of Customers
The bargaining power of customers for Mainz Biomed B.V. is low due to the specialized nature of the company's products and services.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Mainz Biomed B.V. is medium due to the availability of multiple suppliers for raw materials and equipment.
Threat Of New Entrants
The threat of new entrants for Mainz Biomed B.V. is high due to the growing demand for cancer diagnostics and the potential for new companies to enter the market.
Intensity Of Rivalry
The intensity of rivalry for Mainz Biomed B.V. is high due to the competitive nature of the cancer diagnostics market and the presence of established companies.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 69.55% |
| Debt Cost | 5.35% |
| Equity Weight | 30.45% |
| Equity Cost | 5.35% |
| WACC | 5.35% |
| Leverage | 228.39% |
Mainz Biomed B.V. : Quality Control
Mainz Biomed B.V. passed 1 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| CNTG | Centogene N.V., together with its subsidiaries, focuses on rare diseases that transforms real-world clinical and genetic, or other data into actionable information for patients, physicians, and pharmaceutical companies worldwide. It … |
| VIMIAN.ST | Vimian Group AB (publ) engages in the animal health business worldwide. It operates through Specialty Pharma, MedTech, Diagnostics, and Veterinary Services segments. The company offers proprietary diagnostics, prescription, and non-prescription … |
| SLV.WA | Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. … |
| LBIRD.PA | Lumibird SA designs, manufactures, and sells various lasers for the scientific, industrial, and medical applications worldwide. It operates in two divisions, Photonics and Medical. The Photonics division offers solid-state lasers, … |
| MLEC | Moolec Science SA, a science-based ingredient company, focuses on producing animal proteins in plants through Molecular Farming, a disruptive technology in the alternative protein landscape. The company's product portfolio and … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Mainz Biomed
A-Score
1-Year Total Return ->
🥈
Selvita
A-Score
1-Year Total Return ->
🥉
Centogene
A-Score
1-Year Total Return ->
4
Moolec Science
A-Score
1-Year Total Return ->
5
Vimian Group
A-Score
1-Year Total Return ->
6
